Results 61 to 70 of about 60,692 (294)

Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure

ESC Heart Failure, Volume 12, Issue 3, Page 2023-2033, June 2025.
Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone.
Shodai Kawanami, Yasuyuki Egami, Masaru Abe, Mizuki Osuga, Hiroaki Nohara, Kohei Ukita, Akito Kawamura, Koji Yasumoto, Naotaka Okamoto, Yasuharu Matsunaga‐Lee, Masamichi Yano, Masami Nishino   +11 more
wiley   +1 more source

Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study [PDF]

, 2012
<p>Background: Randomized controlled trials have shown the importance of tight glucose control in type 1 diabetes (T1DM), but few recent studies have evaluated the risk of cardiovascular disease (CVD) and all-cause mortality among adults with T1DM.
Andrew D. Morris, Donald W. M. Pearson, Eleanor J. Hothersall, Frank Sullivan, Graham P. Leese, Helen C. Looker, Helen M. Colhoun, John Chalmers, John McKnight, John R. Petrie, Naveed Sattar, Norman R. Peden, Richard Lehman, Robert S. Lindsay, Sam Philip, Sarah H. Wild, Shona J. Livingstone, Stephen Cleland   +17 more
core   +6 more sources

The Diabetic Buddy: A Diet Regulator andTracking System for Diabetics [PDF]

arXiv, 2021
The prevalence of Diabetes mellitus (DM) in the Middle East is exceptionally high as compared to the rest of the world. In fact, the prevalence of diabetes in the Middle East is 17-20%, which is well above the global average of 8-9%. Research has shown that food intake has strong connections with the blood glucose levels of a patient.
arxiv  

The efficacy and safety of sodium‐glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure

ESC Heart Failure, Volume 12, Issue 3, Page 2087-2097, June 2025.
Abstract Aims Sodium‐glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) have demonstrated effectiveness in reducing cardiovascular death and heart failure hospitalization (HFH). However, the efficacy and safety of SGLT2 inhibitors in elderly patients with poor general status, such as very low bodyweight or low nutritional status, who are not included ...
Kenji Nakano, Kenji Kanenawa, Akihiro Isotani, Takashi Morinaga, Kaori Yamamoto, Norihisa Miyawaki, Euihong Ko, Miho Nakamura, Yuichi Tanaka, Kenichi Ishizu, Toru Morofuji, Masaomi Hayashi, Masato Fukunaga, Makoto Hyodo, Shinichi Shirai, Kenji Ando   +15 more
wiley   +1 more source

An audit of the management of diabetic ketoacidosis at St Luke’s Hospital [PDF]

, 2008
Aim: To perform an audit of the protocol used in the management of patients with Diabetic Ketoacidosis, in St Lukes Hospital. Methods: Patients admitted with `Diabetes Ketoacidosis', between 14th August 2004 and 14th August 2005, were identified from the
Abela, Alexia-Giovanna, Azzopardi, Joseph, Calleja, Neville, Debono, Miguel, Magri, Caroline Jane, Vassallo, Josanne   +5 more
core  

Prescription of guideline‐directed medical therapy in heart failure: impact on mortality and readmission

ESC Heart Failure, EarlyView.
Routine data analysis showing a better outcome regarding mortality and readmission in HF patients when being prescribed the current four‐drug treatment (vs. the outdated two‐drug therapy) 91–365 days after index hospital stay. Abstract Aims The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy ...
Martin Möckel, Samipa Pudasaini, Kristina Feldmann, Henning Thomas Baberg, Benny Levenson, Jürgen Malzahn, Thomas Mansky, Guido Michels, Christian Günster, Elke Jeschke   +9 more
wiley   +1 more source

ST segment elevation following sinoventricular rhythm in a patient with diabetic ketoacidosis [PDF]

, 2007
Diabetic ketoacidosis is a major cause of morbidity and mortality in patients with insulin dependent diabetes. Myocardial infarction is an uncommon but well-recognised precipitating cause of diabetic ketoacidosis, accounting for 1% of cases.
Altun, Armagan, Tatli, Ersan, Yilmaztepe, Mustafa   +2 more
core   +1 more source

Management of diabetes from preconception to the postnatal period: summary of NICE guidance [PDF]

, 2008
Diabetes in pregnancy is associated with risks to the woman (for example, higher rates of miscarriage, preeclampsia, and preterm labour) and to the developing fetus and baby (for example, higher rates of congenital malformations, macrosomia, birth ...
Guideline Development Group, NICE, Mugglestone, M.   +1 more
core   +3 more sources

Variable Weights Neural Network For Diabetes Classification [PDF]

arXiv, 2021
As witnessed in the past year, where the world was brought to the ground by a pandemic, fighting Life-threatening diseases have found greater focus than ever. The first step in fighting a disease is to diagnose it at the right time. Diabetes has been affecting people for a long time and is growing among people faster than ever. The number of people who
arxiv  

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

ESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta, Manuel Garofalo, Samuele Salvi, Matteo Orlandi, Gianluca Marcaccini, Pietro Susini, Luca Checchi, Alberto Palazzuoli, Carlo Di Mario, Maurizio Pieroni, Matteo Beltrami   +10 more
wiley   +1 more source